Allscripts Healthcare Solutions - MDRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 17.02 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.41 (2.23%)

This chart shows the closing price for MDRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allscripts Healthcare Solutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDRX

Analyst Price Target is $22.00
▲ +17.02% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Allscripts Healthcare Solutions in the last 3 months. The average price target is $22.00, with a high forecast of $26.00 and a low forecast of $17.00. The average price target represents a 17.02% upside from the last price of $18.80.

This chart shows the closing price for MDRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Allscripts Healthcare Solutions. This rating has held steady since March 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2022JPMorgan Chase & Co.Boost TargetUnderweight$19.00 ➝ $20.00Low
11/8/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$22.00 ➝ $23.00Low
11/4/2022Piper SandlerReiterated RatingOverweight$17.00Low
9/15/2022KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
7/12/2022The Goldman Sachs GroupInitiated CoverageNeutral$21.00N/A
6/9/2022Piper SandlerLower Target$19.00 ➝ $17.00Medium
5/6/2022Piper SandlerLower Target$22.00 ➝ $19.00High
3/18/2022Piper SandlerBoost TargetNeutral$19.00 ➝ $22.00High
3/4/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$20.00 ➝ $26.00Medium
3/3/2022SVB LeerinkBoost TargetOutperform$22.00 ➝ $24.00Medium
1/25/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$19.00 ➝ $22.00High
1/25/2022Piper SandlerBoost Target$17.00 ➝ $19.00High
11/23/2021Deutsche Bank AktiengesellschaftBoost TargetHold$18.00 ➝ $20.00Low
11/5/2021Cantor FitzgeraldReiterated RatingNeutralMedium
8/6/2021Piper SandlerReiterated RatingIn-Line ➝ Neutral$15.00 ➝ $17.00Low
8/6/2021SVB LeerinkBoost TargetMarket Perform$17.00 ➝ $19.00High
8/6/2021Royal Bank of CanadaBoost TargetOutperform$17.00 ➝ $19.00High
5/26/2021SVB LeerinkBoost TargetMarket Perform$16.00 ➝ $17.00Medium
5/20/2021Deutsche Bank AktiengesellschaftBoost TargetHold$15.00 ➝ $17.00Low
4/30/2021SVB LeerinkBoost TargetMarket Perform$15.00 ➝ $16.00Low
4/29/2021JPMorgan Chase & Co.Initiated CoverageUnderweightLow
3/8/2021ArgusReiterated RatingBuy ➝ HoldN/A
3/2/2021ArgusDowngradeBuy ➝ HoldHigh
2/26/2021SVB LeerinkLower TargetMarket Perform$16.00 ➝ $15.00High
2/26/2021Piper SandlerLower TargetNeutral$17.00 ➝ $15.00High
2/16/2021Piper SandlerBoost TargetNeutral$11.50 ➝ $17.00Low
11/25/2020Bank of AmericaBoost TargetBuy$14.00 ➝ $16.50Low
11/11/2020ArgusUpgradeHold ➝ Buy$14.00Low
10/23/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.00 ➝ $11.00Low
10/19/2020Robert W. BairdDowngradeOutperform ➝ Neutral$13.00High
10/14/2020Cantor FitzgeraldBoost TargetNeutral$9.00 ➝ $13.00High
10/14/2020SVB LeerinkBoost TargetMarket Perform$10.00 ➝ $13.00High
8/24/2020JPMorgan Chase & Co.Boost TargetNeutral$8.00 ➝ $9.00Low
8/11/2020Morgan StanleyBoost TargetUnderweight$6.00 ➝ $8.00High
8/3/2020Royal Bank of CanadaBoost TargetOutperform$8.00 ➝ $10.00High
7/31/2020Cantor FitzgeraldBoost TargetHold ➝ Neutral$6.00 ➝ $9.00High
7/31/2020SVB LeerinkBoost TargetMarket Perform$6.00 ➝ $10.00Low
7/21/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$6.50 ➝ $5.50High
6/11/2020Deutsche Bank AktiengesellschaftLower TargetHold$11.00 ➝ $9.00High
5/13/2020Morgan StanleyBoost TargetUnderweight$5.00 ➝ $6.00Low
5/13/2020SunTrust BanksBoost TargetHold$6.00 ➝ $7.00High
5/10/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
5/8/2020SVB LeerinkLower TargetMarket Perform$8.00 ➝ $6.00Medium
5/8/2020Cantor FitzgeraldReiterated RatingNeutral$8.00 ➝ $6.00High
4/22/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$10.50 ➝ $7.00High
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$8.00Medium
4/13/2020SVB LeerinkInitiated CoverageMarket Perform$8.00High
3/5/2020SunTrust BanksLower TargetHold$11.00 ➝ $9.00High
3/4/2020Deutsche Bank AktiengesellschaftLower TargetHold$12.00 ➝ $11.00High
3/3/2020Dougherty & CoReiterated RatingBuyHigh
3/3/2020Piper SandlerLower Target$12.00 ➝ $9.50High
3/3/2020CfraLower TargetStrong Sell$9.00 ➝ $6.00Medium
3/3/2020Robert W. BairdLower TargetOutperform$13.00 ➝ $10.00High
3/3/2020Cantor FitzgeraldReiterated RatingNeutral$11.00 ➝ $8.00High
11/26/2019UBS GroupInitiated CoverageNeutral$11.50Low
11/5/2019Cantor FitzgeraldReiterated RatingNeutralMedium
9/26/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$11.00Low
8/23/2019Jefferies Financial GroupInitiated CoverageBuy$13.00High
8/12/2019Robert W. BairdSet TargetBuy$13.00Medium
8/11/2019Evercore ISIReiterated RatingHold$11.50Low
5/2/2019Cantor FitzgeraldReiterated RatingHold$10.00High
2/22/2019CitigroupDowngradeBuy ➝ Neutral$14.00 ➝ $12.00High
11/14/2018ArgusDowngradeBuy ➝ HoldLow
11/2/2018Robert W. BairdLower TargetOutperform ➝ Outperform$16.00 ➝ $14.00Low
11/2/2018CitigroupLower TargetBuy ➝ Buy$19.00 ➝ $17.00Low
11/2/2018Bank of AmericaLower TargetBuy ➝ Buy$16.50 ➝ $15.00High
11/2/2018SunTrust BanksDowngradeBuy ➝ HoldHigh
11/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$16.00 ➝ $12.00High
11/1/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$12.00High
8/3/2018Royal Bank of CanadaReiterated RatingBuy$14.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$17.00High
6/8/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
5/4/2018Bank of AmericaLower TargetBuy ➝ Buy$17.00 ➝ $15.50High
5/4/2018Maxim GroupReiterated RatingBuy$18.00High
5/4/2018SunTrust BanksUpgradeHold ➝ Buy$10.78 ➝ $16.13High
5/3/2018Cantor FitzgeraldReiterated RatingBuy$18.00Medium
4/24/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$16.00High
4/5/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
3/6/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
2/27/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$17.00Low
2/17/2018Wells Fargo & CompanySet TargetBuy$19.00High
1/28/2018Cantor FitzgeraldReiterated RatingBuy$17.00Low
1/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$17.50Medium
1/16/2018SunTrust BanksDowngradeBuy ➝ HoldHigh
1/11/2018Royal Bank of CanadaSet TargetBuy$19.00High
1/9/2018Maxim GroupReiterated RatingBuy$20.00Medium
1/8/2018Cantor FitzgeraldReiterated RatingBuy$17.00Low
1/4/2018CitigroupInitiated CoverageBuyLow
(Data available from 11/30/2017 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Allscripts Healthcare Solutions logo
Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $18.80
Low: $18.30
High: $18.82

50 Day Range

MA: $16.02
Low: $13.85
High: $18.60

52 Week Range

Now: $18.80
Low: $13.59
High: $23.25


48,797 shs

Average Volume

1,437,421 shs

Market Capitalization

$2.05 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Allscripts Healthcare Solutions?

The following Wall Street sell-side analysts have issued reports on Allscripts Healthcare Solutions in the last year: Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Piper Sandler,, SVB Leerink LLC, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for MDRX.

What is the current price target for Allscripts Healthcare Solutions?

5 Wall Street analysts have set twelve-month price targets for Allscripts Healthcare Solutions in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 17.0%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting MDRX will reach $26.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $17.00 for Allscripts Healthcare Solutions in the next year.
View the latest price targets for MDRX.

What is the current consensus analyst rating for Allscripts Healthcare Solutions?

Allscripts Healthcare Solutions currently has 1 sell rating, 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDRX will outperform the market and that investors should add to their positions of Allscripts Healthcare Solutions.
View the latest ratings for MDRX.

What other companies compete with Allscripts Healthcare Solutions?

How do I contact Allscripts Healthcare Solutions' investor relations team?

Allscripts Healthcare Solutions' physical mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The software maker's listed phone number is (800) 334-8534 and its investor relations email address is [email protected] The official website for Allscripts Healthcare Solutions is Learn More about contacing Allscripts Healthcare Solutions investor relations.